Pharma Co. Impel Hits Ch. 11 With $127M Debt And Sale Plans
Migraine-drug maker Impel Pharmaceuticals Inc. and one of its subsidiaries filed for bankruptcy in Texas, listing $126.9 million in debt and plans to sell itself as a going concern....To view the full article, register now.
Already a subscriber? Click here to view full article